{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-306032","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.085042+00:00","generated_at":"2026-06-07T05:44:08.648671+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexicon enters $75M at-the-market equity offering agreement with Jefferies","bullets":["Company may sell up to $75M of common stock through Jefferies in at-the-market offerings.","Jefferies receives 3.0% commission on gross proceeds; company also reimburses legal fees.","Invus affiliate (largest stockholder) has right to purchase shares to maintain ownership, subject to conditions.","Proceeds intended to fund commercial launch of INPEFA (sotagliflozin), R&D, and working capital.","Shares issued under existing shelf registration; prospectus supplement filed Dec 29, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-306032","json":"https://secwatch.observer/filing/0001193125-23-306032.json","markdown":"https://secwatch.observer/filing/0001193125-23-306032.md","text":"https://secwatch.observer/filing/0001193125-23-306032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/0001193125-23-306032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/d673597d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:44:08.648671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60d65819d40d179ee4a7577305cae90d36a62d4d","claim":"LEXICON PHARMACEUTICALS, INC. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $75,000,000 (effective 2023-12-29).","evidence_excerpt":"On December 29, 2023, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”) entered into an Open Market Sale Agreement SM (the “ Agreement ”) with Jefferies LLC, as sales agent (“ Jefferies ”), pursuant to which the Company may offer and sell, from time to time, through Jefferies (the “public offerings”), shares of its common stock, par value $0.001, having an aggregate sales price of up to $75,000,000 (the “ Shares ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312523306032/0001193125-23-306032-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"up to $75,000,000"},{"label":"Effective","value":"2023-12-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}